Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 300-305

  Nieder, Carsten ^a,e   Astner, Sabrina T ^b   Mehta, Minesh P ^c   Grosu, Anca L ^d   Molls, Michael ^b  

^a Oncology and Radiation Oncology Units ^*  (Norway)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Corticosteroid; Dexamethasone; Glioblastoma; Radiotherapy; Re irradiation; Recurrent glioma

Indexed keywords

CARMUSTINE; CELECOXIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOTEMUSTINE; GEFITINIB; HYDROXYUREA; IMATINIB; IODINE 125; IRINOTECAN; LOMUSTINE; PROCARBAZINE; STEROID; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; OVERALL SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; REVIEW; STEREOTACTIC TREATMENT; TOXICITY; ADJUVANT THERAPY; ADULT; BRAIN TUMOR; DISEASE FREE SURVIVAL; METHODOLOGY; MORTALITY; PALLIATIVE THERAPY; RADIOTHERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE;

EID: 44949158990     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815e3fdc     Document Type: Review

References (36)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
2. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Rev. 2000;26:397-409.
3. Nieder C, Adam M, Molls M, et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Haematol. 2006;60:181-193.
4. Veninga T, Langendijk HA, Slotman BJ, et al. Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol. 2001;59:127-137.
5. Arcicasa M, Roncadin M, Bidoli E, et al. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;43:789-793.
6. Nieder C, Nestle U, Niewald M, et al. Hyperfractionated reirradiation for malignant glioma. Front Radiat Ther Oncol. 1999;33:150-157.
7. Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167-171.
8. Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55.
9. Hudes RS, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:293-298.
10. Shepherd SF, Laing RW, Cosgrove VP, et al. Hypofractionated stereo-tactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393-398.
11. Ernst-Stecken A, Ganslandt O, Lambrecht U, et al. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol. 2007;81:287-294.
12. Kohshi K, Yamamoto H, Nakahara A, et al. Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol. 2007;82:297-303.
13. Wurm RE, Kuczer DA, Schlenger L, et al. Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 2006;66:S26-S32.
14. Cho KH, Hall WA, Gerbi BJ, et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;45:1133-1141.
15. Combs SE, Widmer V, Thilmann C, et al. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme. Cancer. 2005;104:2168-2173.
16. Simon JM, Cornu P, Boisserie G, et al. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys. 2002;53:67-74.
17. Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblas-toma multiforme with gliasite brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:1133-1139.
18. Brazil L, Thomas R, Laing R, et al. Verbally administered Barthel Index as functional assessment in brain tumor patients. J Neurooncol. 1997; 34:187-192.
19. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511-519.
20. Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006;58:701-709.
21. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multi-forme. J Neurooncol. 2007;81:53-60.
22. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 2005;63:47-55.
23. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neurooncol. 2007;9:29-38.
24. Kappelle AC, Postma TJ, Taphoorn MJB, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118-120.
25. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? Neurology. 2004;63:1281-1284.
26. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004; 22:4727-4734.
27. Burch PA, Bernath AM, Cascino TL, et al. A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs. 2000;18:275-280.
28. Chang SM, Theodosopoulos P, Lamborn K, et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004;100:605-611.
29. Prados MD, Yung WK, Fine HA, et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neurooncol. 2004;6:33-37.
30. Chua SL, Rosenthal MA, Wong SS, et al. Phase 2 study of temozolo-mide and Caelyx in patients with recurrent glioblastoma multiforme. Neurooncol. 2004;6:38-43.
31. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neurooncol. 2007;9:354-363.
32. Silvani A, Lamperti E, Gaviani P, et al. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozo-lomide treated recurrent glioblastoma patients. J Neurooncol. 2007; epub ahead of print.
33. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multi-forme. J Clin Oncol. 2005;23:9359-9368.
34. Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007; 96:1047-1051.
35. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24:3651-3656.
36. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain me-tastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291-298.